<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02232399</url>
  </required_header>
  <id_info>
    <org_study_id>MiLe-1</org_study_id>
    <secondary_id>2013-003105-25</secondary_id>
    <nct_id>NCT02232399</nct_id>
  </id_info>
  <brief_title>Is Levosimendan Superior to Milrinone Regarding Acute Kidney Injury After Cardiac Surgery for Congenital Heart Disease?</brief_title>
  <acronym>MiLe-1</acronym>
  <official_title>The Prophylactic Effect of Levosimendan in Reducting Acute Kidney Injury Postoperatively in Pediatric Patients Undergoing Corrective Heart Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Göteborg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the ability of Levosimendan to reduce the postoperative&#xD;
      acute kidney injury in pediatric patients undergoing surgery for congenital heart disease&#xD;
      (CHDs). Young children, between the age of 1 to 12 months, with congenital heart disease in&#xD;
      need of elective heart surgery will be included in this study.&#xD;
&#xD;
      The trial will contain two study groups, 35 patients in each. One group will receive&#xD;
      Levosimendan and the second group will receive Milrinone as a heart muscle-strengthening&#xD;
      agent during and after the operation. Milrinone is currently used as the drug of choice in&#xD;
      many pediatric cardiac surgery centers. It remains to see if Levosimendan can exert a kidney&#xD;
      protecting function in addition to its heart muscle-strengthening properties.&#xD;
&#xD;
      The primary objective of this study is to investigate the preventive effect of Levosimendan&#xD;
      on postoperative acute kidney injury in pediatric patients undergoing surgery for their CHDs.&#xD;
      Creatinine levels postoperatively will be the primary endpoint. Creatinine, the common marker&#xD;
      of kidney injury, will be measured daily.&#xD;
&#xD;
      The treatment with Levosimendan or Milrinone will be started during the operation (after&#xD;
      initiation of cardiopulmonary bypass) and will last 24 hours. Blood samples will be obtained&#xD;
      at six occasions perioperatively. Patients will be followed 4 days after termination of&#xD;
      treatment (totally 5 days).&#xD;
&#xD;
      The duration of study will be 30 days (24 hours treatment + 4 days follow up +&#xD;
      30-days-mortality registration).&#xD;
&#xD;
      Creatinine is the primary outcome in this study. Inflammatory biomarkers and other relevant&#xD;
      biomarkers will comprise the secondary outcome variables.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">April 25, 2017</completion_date>
  <primary_completion_date type="Actual">April 25, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>Second postoperative day</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Congenital Heart Defects</condition>
  <arm_group>
    <arm_group_label>Milrinone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this arm the patients will receive Milrinone as an inotrope agent. Concentration: 0.2 mg/mL Infusion rate: 0.12 mL / kg / hr = Dose delivered 0.4 μg / kg / min --- Bolus dose: 1.44 ml / kg / hr in ten minutes (a maximum volume 0.24 ml / kg) = 48 μg / kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levosimendan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm the patients will receive Levosimendan as an inotrope agent. Concentration: 0.05 mg/mL Infusion rate: 0.12 mL / kg / hr = Dose delivered 0.1 μg / kg / min --- Bolus dose: 1.44 ml / kg / hr in ten minutes (a maximum volume 0.24 ml / kg) = 12 μg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levosimendan</intervention_name>
    <description>The drug infusion will be started after initiation of cardiopulmonary bypass and will continue for 24 hours.</description>
    <arm_group_label>Levosimendan</arm_group_label>
    <other_name>Simdax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milrinone</intervention_name>
    <description>The drug infusion will be started after initiation of cardiopulmonary bypass and will continue for 24 hours.</description>
    <arm_group_label>Milrinone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of informed consent prior to any study specific procedures&#xD;
&#xD;
          2. Female and male children between 1 and 12 months of age&#xD;
&#xD;
          3. Non-restrictive VSD (corrective surgery)&#xD;
&#xD;
          4. Complete AVSD (biventricular repair)&#xD;
&#xD;
          5. Tetralogy of Fallot&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unbalanced AtrioVentricular Septal Defect or AVSD with cyanosis&#xD;
&#xD;
          2. Age less than one month and more than one year&#xD;
&#xD;
          3. Acute operation that is unscheduled operation during the first 24 hours after&#xD;
             presentation to the department for thoracic surgery&#xD;
&#xD;
          4. Mild, moderate, or severe kidney dysfunction and known anatomical anomalies of kidneys&#xD;
&#xD;
          5. Liver impairment or disease&#xD;
&#xD;
          6. Ongoing infection&#xD;
&#xD;
          7. Use of nephrotoxic drugs (like ibuprofen, angiotensin-converting-enzyme inhibitors,&#xD;
             gentamicin, vancomycin) preoperative or postoperative until first post operative day.&#xD;
             Contrast agents whithin 24 hours before operation.&#xD;
&#xD;
          8. Use of inhibitors of membrane transport proteins (cimetidine, cetirizine,&#xD;
             trimethoprim, probenecid, rifampin and gemfibrosil).&#xD;
&#xD;
          9. Allergy to Levosimendan or substance included in the preparation or previous use of&#xD;
             Levosimendan.&#xD;
&#xD;
         10. Severe arrhythmias needing pace-maker treatment prior to the operation&#xD;
&#xD;
         11. Severe cardiac dysfunction needing for treatment with extracorporeal membrane&#xD;
             oxygenation (ECMO) prior to the operation.&#xD;
&#xD;
         12. Preoperative need for mechanical ventilation and/or inotropic agents.&#xD;
&#xD;
         13. Re-operation (open heart surgery). Earlier surgical closure of the arterial duct does&#xD;
             not count as an exclusion criteria.&#xD;
&#xD;
         14. Prematurity: Gestational age &lt; 30 weeks, irrespective of postpartum age. Gestational&#xD;
             age 30-34 weeks if patient is included at postpartum age under 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>12 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Castellheim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Silvia Children´s Hospital, Department of anesthesia and intensive care</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Håkan Wåhlander, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Queen Silvia Children´s Hospital, Department of pediatric cardiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Birgitta Romlin, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Queen Silvia Children´s Hospital, Department of anesthesiology and intensive care</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elin Thorlacius, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Queen Silvia Children´s Hospital, Department of anesthesiology and intensive care</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sven-Erik Ricksten, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Sahlgrenska University Hospital, Department of anesthesiology and intensive care</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children´s Hospital, Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>FIN-00029 HYKS</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Silvia Children´s Hospital</name>
      <address>
        <city>Göteborg</city>
        <state>Västra Götaland</state>
        <zip>416 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>September 2, 2014</study_first_submitted>
  <study_first_submitted_qc>September 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2014</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Göteborg University</investigator_affiliation>
    <investigator_full_name>Albert Castellheim</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simendan</mesh_term>
    <mesh_term>Milrinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

